Magnetic resonance imaging features of the nigrostriatal system: Biomarkers of Parkinson's disease stages?

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Hopes, Lucie ^a,b   Grolez, Guillaume ^a,b   Moreau, Caroline ^a,b   Lopes, Renaud ^a,b   Ryckewaert, Gilles ^a   Carrière, Nicolas ^a,b   Auger, Florent ^b,c   Laloux, Charlotte ^b,c   Petrault, Maud ^b,c   Devedjian, Jean Christophe ^b,c   Bordet, Regis ^b,c   Defebvre, Luc ^a,b   Jissendi, Patrice ^a,b   Delmaire, Christine ^a,b   Devos, David ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CHU Lille   (France)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BIOLOGICAL MARKER; IRON;

ADULT; ADVANCE STAGE; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BRAIN HISTOLOGY; BRAIN LEVEL; CAUDATE NUCLEUS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; EARLY STAGE; FEMALE; FOCAL STRIATUM ATROPHY; FOLLOW UP; HUMAN; IN VIVO STUDY; IRON OVERLOAD; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOUSE; MPTP-INDUCED PARKINSONISM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL STRIATUM ATROPHY; PARKINSON DISEASE; PUTAMEN; R2 VALUE; RADIOLOGICAL PARAMETERS; STAGING; STRATIAL SHAPE ANALYSIS; STRATIAL VOLUME ANALYSIS; SUBSTANTIA NIGRA; ACUTE DISEASE; ANIMAL; C57BL MOUSE; COMPLICATION; CORPUS STRIATUM; MIDDLE AGED; OXIDATIVE STRESS; PATHOLOGY; PROCEDURES;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACUTE DISEASE; AGED; ANIMALS; BIOMARKERS; CORPUS STRIATUM; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IRON; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MALE; MICE, INBRED C57BL; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA;

EID: 84962860757     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147947     Document Type: Article

References (30)

1. Napolitano A, Manini P, D'Ischia M. Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr Med Chem 2011;18:1832-1845. PMID: 21466469
2. Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987;2:1219-1220. PMID: 2890848
3. Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 1993;4:61-65. PMID: 8358514
4. Wallis LI, Paley MN, Graham JM, Grünewald RA, Wignall EL, Joy HM et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008;28:1061-1067. doi: 10. 1002/jmri.21563 PMID: 18972346
5. Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, et al. Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. Brain 2010;133:3423-3433. doi: 10.1093/brain/awq212 PMID: 20736190
6. Bunzeck N, Singh-Curry V, Eckart C, Weiskopf N, Perry RJ, Bain PG, et al. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease. Parkinsonism Relat Disord 2013;19:1136-1142. doi: 10.1016/j.parkreldis.2013.08.011 PMID: 24025315
7. ∗ and diffusion tensor imaging changes in the substantia nigra in Parkinson's disease. Mov Disord 2011;26:1627-1632. doi: 10.1002/mds.23643 PMID: 21618607
8. Martin WRW, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: A potential biomarker of disease status. Neurology 2008;70; 1411-1417. doi: 10.1212/01.wnl.0000286384.31050.b5 PMID: 18172063
9. ∗ a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PLoS One Published online first: 1st March 2013. doi: 10.1371/journal.pone.0057904
10. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014;21:195-210. doi: 10.1089/ars.2013.5593 PMID: 24251381
11. Aquino D, Contarino V, Albanese A, Minati L, Farina L, Grisoli M, et al. Substantia nigra in Parkinson's disease: a multimodal MRI comparison between early and advanced stages of the disease. Neurol Sci 2014;35:753-758. doi: 10.1007/s10072-013-1595-2 PMID: 24337946
12. Geng DY, Li YX, Zee CS. Magnetic Resonance Imaging-Based Volumetric Analysis of Basal Ganglia Nuclei and Substantia Nigra in Patients with Parkinson's Disease. Neurosurgery 2006;58:256-262. PMID: 16462479
13. Pitcher TL, Melzer TR, Macaskill MR, Graham CF, Livingston L, Keenan RJ, et al. Reduced striatal volumes in Parkinson's disease: a magnetic resonance imaging study. Transl Neurodegener 2012;1:17. doi: 10.1186/2047-9158-1-17 PMID: 23210661
14. Apostolova LG, Beyer M, Green AE, Hwang KS, Morra JH, Chou YY, et al. Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. MovDisord 2010;25:687e8.
15. Styner M, Oguz I, Xu S, Brechbühler C, Pantazis D, Levitt JJ, et al. Framework for the statistical shape analysis of brain structures using SPHARM-PDM. Insight J 2006a; 242.
16. Carriere N, Besson P, Dujardin K, Duhamel A, Defebvre L, Delmaire C, et al. Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: a magnetic resonance imaging shape analysis. Mov Disord 2014;29:897-903. doi: 10.1002/mds.25904 PMID: 24817690
17. Sterling NW, Du G, Lewis MM, Dimaio C, Kong L, Eslinger PJ, et al. Striatal shape in Parkinson's disease. Neurobiol Aging 2013;34:2510-2516. doi: 10.1016/j.neurobiolaging.2013.05.017 PMID: 23820588
18. Lee HM, Kwon KY, Kim MJ, Jang JW, Suh SI, Koh SB, et al. Subcortical grey matter changes in untreated, early stage Parkinson's disease without dementia. Parkinsonism Relat Disord 2014;20:622-626. doi: 10.1016/j.parkreldis.2014.03.009 PMID: 24703894
19. Daniel SE, Lees AJ. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993;39:165-172. PMID: 8360656
20. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707. PMID: 17542011
21. APA. Diagnostic and statistical manual of mental disorders, 4th edn, text revision. Arlington, VA: American Psychiatric Association 2000.
22. Laloux C, Petrault M, Lecointe C, Devos D, Bordet R. Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease. Pharmacol Res 2012;65:514-522. doi: 10.1016/j.phrs.2012.02.008 PMID: 22391246
23. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958;3:41-51. PMID: 13611557
24. ∗ and T2' in brain parenchyma. AJNR Am J Neuroradiol 2008;29:950-955. doi: 10.3174/ajnr. A0951 PMID: 18272561
25. Rossi ME, Ruottinen H, Saunamäki T, Elovaara I, Dastidar P. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages. Acad Radiol 2014;21:64-71. doi: 10. 1016/j.acra.2013.09.018 PMID: 24331266
26. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003;37:899-909. PMID: 12670420
27. You LH, Li F, Wang L, Zhao SE, Wang SM, Zhang LL, et al. Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson's disease Neuroscience 2015;22:234-246.
28. Haegelen C, Coupé P, Fonov V, Guizard N, Jannin P, Morandi X, et al. Automated segmentation of basal ganglia and deep brain structures in MRI of Parkinson's disease. Int J Comput Assist Radiol Surg 2012;18.
29. Kwon DH, Kim JM, Oh SH, Jeong HJ, Park SY, Oh ES, et al. Seven-Tesla magnetic resonance images of the substantia nigra in Parkinson disease. Ann Neurol 2012;71:267-77. doi: 10.1002/ana.22592 PMID: 22367998
30. Minati L, Grisoli M, Carella F, De Simone T, Bruzzone MG, Savoiardo M. Imaging degeneration of the substantia nigra in Parkinson disease with inversion-recovery MR imaging. AJNR Am J Neuroradiol 2007;28:309-313. PMID: 17297002